Recombinant Human DNMT1, GST-tagged

• Cat.No.: DNMT1-511H
• Product Overview: Recombinant Human DNMT1, (a-a 2-1632), with N-terminal GST tag expressed inbaculovirus. MW= 211 kDa.

Specification

• Species: Human
• Source: Insect Cells
• Tag: GST
• Protein Length: 2-1632 a.a.
• Description: DNA (cytosine-5-)-methyltransferase 1 has a role in the establishment and regulation of tissue-specific patterns of methylated cytosine residues. Aberrant methylation patterns are associated with certain human tumors and developmental abnormalities.
• Purity: >50%.
• Application: Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
• Formulated In: 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.05% Tween-20 and 10% glycerol.
• Stability: >6 months at –80°C.

Gene Information

• Gene Name: DNMT1 DNA (cytosine-5-)-methyltransferase 1 [ Homo sapiens ]
• Synonyms: DNMT1; DNA (cytosine-5-)-methyltransferase 1; AIM; DNMT; MCMT; CXXC9; FLJ16293; MGC104992; CXXC finger protein 9; DNA methyltransferase 1; EC 2.1.1.37; Dnmt1; DNA methyltransferase HsaI; DNA MTase HsaI; M.HsaI; CXXC-type zinc finger protein 9
• Gene ID: 1786
• mRNA Refseq: NM_001130823
• Protein Refseq: NP_001124295
• MIM: 126375
• UniProt ID: P26358
• Chromosome Location: 19p13.2
• Pathway: Cysteine and methionine metabolism; Metabolic pathways
• Function: DNA (cytosine-5-)-methyltransferase activity; DNA binding; metal ion binding; transcription factor binding; transferase activity; zinc ion binding

Case Study

Case 1: Chen Z, et al. Epigenetics. 2023

While DNMT inhibitors show limited efficacy in solid tumors, this study reveals DNMT1’s role in regulating 5-Azacytidine sensitivity and MEK/ERK signaling in gastric cancer (GC). KRAS mutations or MEK/ERK activation elevate DNMT1 levels, whereas MEK inhibition reduces them. 5-Azacytidine suppresses DNMTs, paradoxically activating MEK/ERK and altering Selumetinib response. TCGA data link DNMT1 expression to RAS/MEK/ERK-driven gene signatures, suggesting combination therapies targeting epigenetic and signaling pathways could overcome resistance.

Fig1. The protein expression of DNMT1 in seven GC cell lines and immortalized normal epithelial GES-1 cells was detected by western blotting.

Fig2. Western blotting analysis of p-Erk1/2 level and DNMT1 expression level in seven GC cells and immortalized epithelial GES-1 cells.

Case 2: Zeng H, et al. Respir Res. 2020

This study links oxidative stress, apoptosis, and DNA methylation in emphysema pathogenesis. COPD patients exhibited elevated ROS, lung apoptosis, and Bcl-2 promoter hypermethylation alongside upregulated DNMT1. In smoking-induced mouse models, antioxidant treatment or DNMT1 inhibition reduced ROS, restored Bcl-2 expression via promoter demethylation, and mitigated emphysema progression. Findings highlight DNMT1-mediated epigenetic dysregulation as a key bridge between oxidative stress and apoptosis, suggesting dual targeting of ROS and DNA methylation could slow COPD advancement.

Fig1. Immunoblotting was conducted in lungs from the control, CS exposure and CS exposure with Vit E treatment groups.

Fig2. Immunoblotting was conducted using lungs from the vector, CS + vector, CS + DNMT1 shRNA and CS + AZA groups.

Application

1. Recombinant DNMT1 Protein: A Key Tool in Epigenetic Research and Disease Therapeutics Recombinant DNMT1 (DNA methyltransferase 1) protein is increasingly utilized to study and modulate DNA methylation, a critical epigenetic mechanism governing gene expression. In cancer research, DNMT1 overexpression is linked to tumor suppressor gene silencing, making recombinant DNMT1 valuable for developing targeted epigenetic therapies. For example, it aids in screening small-molecule inhibitors like 5-Azacytidine to reverse aberrant methylation in leukemia and solid tumors. Its role in maintaining methylation patterns also supports stem cell differentiation studies and regenerative medicine applications, particularly in age-related disorders. 2. Biotechnological Production and Functional Applications Advanced expression systems, including mammalian and insect cell platforms, enable high-yield production of bioactive recombinant DNMT1. Purification techniques such as affinity chromatography ensure enzymatic fidelity for in vitro methylation assays and drug discovery pipelines. Researchers employ recombinant DNMT1 to model methylation dysregulation in neurodegenerative diseases like Alzheimer’s, where epigenetic alterations contribute to pathology. Additionally, it is integrated into diagnostic tools to assess methylation biomarkers for early cancer detection or monitor therapeutic responses in real time. 3. Future Prospects in Precision Epigenetics Ongoing studies explore recombinant DNMT1’s potential in combination therapies, such as pairing DNMT inhibitors with immune checkpoint blockers to enhance cancer treatment efficacy. CRISPR-DNMT1 fusion systems are being engineered for locus-specific methylation editing, offering precision in correcting epigenetic defects. Collaborations between academia and biotech firms aim to optimize delivery mechanisms, including nanoparticle carriers, to improve in vivo stability. As DNA methylation’s role in aging and metabolic diseases gains focus, recombinant DNMT1 is poised to drive innovations in personalized epigenetic medicine.

Fig1. DNMT1 mediates multiple PCD. (Lan Yan, 2023)